Eric Coldwell

Shares of pharmacy retailer Walgreens Boots Alliance Inc (NASDAQ: WBA) ended 2020 lower by nearly 30%, but Baird sees several catalysts for the company that it said should put an end to years of "train wreck" performance. The Walgreens Analyst: Eric Coldwell upgraded...

CVS Health Corp (NYSE: CVS) laid out its ideas for growing earnings growth from the low single digits expected next year, giving analysts a look at a plan that includes a turnaround in its retail long-term care business, growth at its acquired health insurer Aetna and faster-than-expected ramp up...

Walgreens Boots Alliance Inc (NASDAQ: WBA) plunged Friday when Baird added the stock to its "Fresh Pick Negative List." “We think they're going to struggle with upper bounds of guidance,” analyst Eric Coldwell told Benzinga. The Rating Coldwell maintained a Neutral rating...

Retail pharmacy chain Rite Aid Corporation (NYSE: RAD) announced a renewal of its contract Wednesday with pharmaceutical distributor McKesson Corporation (NYSE: MCK) through 2029. What Happened McKesson will continue sourcing and offering Rite Aid delivery of branded and generic drugs...

Regulatory uncertainty is rising too high for Baird Equity Research to remain bullish on Express Scripts Holding Co (NASDAQ: ESRX). The Rating Analyst Eric Coldwell downgraded Express Scripts to Neutral with an $81 price target. The Thesis Previously, Express Scripts’ improving new business...

Laboratory Corp. of America Holdings (NYSE: LH) shares have gained about 7 percent year-to-date period versus Quest Diagnostics Inc (NYSE: DGX)'s 2.3-percent advance. At least one analyst thinks it's worth plowing fresh money into LabCorp rather than Quest, although they aren't...

Some see Walgreens Boots Alliance Inc (NASDAQ: WBA)’s reported pursuit of AmerisourceBergen Corp. (NYSE: ABC) as a smart defensive play. The purchase would cut costs in the drug supply chain, increase appeal with pharmacy benefit managers and insurers and strengthen the drugstore operator...

Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...

CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET) agreed to merge over the weekend, and some of Wall Street's top analysts released their initial take on the deal. The Analyst Baird's Eric Coldwell maintains a Neutral rating on CVS' stock with an unchanged $77 price target...

"Taking a flyer" on McKesson Corporation (NYSE: MCK), as per its recent assertion that it would take a call at the right time, Baird upgraded shares of the company. The firm noted that the company's shares have materially underperformed in the year-to-date period as well as the trailing 12-month...

It’s been a rough summer for the tobacco industry. After the U.S. Food and Drug Administration announced plans to limit nicotine intake, the New York City Council voted Thursday to raise the price of cigarettes, halve the number of licensed retailers and, in a move causing more widespread...

Express Scripts Holding Company (NASDAQ: ESRX) shares are down more than 13 percent after the company announced it is likely losing Anthem Inc (NYSE: ANTM), its largest client, after Anthem’s current contract ends in 2019. Growing Concerns The news is obviously a blow to Express’s...

Ahead of Walgreens Boots Alliance Inc (NASDAQ: WBA)'s fiscal year second-quarter results, Baird updated its view on the company with its new Rite Aid Corporation (NYSE: RAD)'s assumptions. Walgreens is scheduled to release its quarterly results before the markets open on April 5, 2017. Walgreen's...

Baird downgraded Quintiles IMS Holdings Inc (NYSE: Q) to Underperform, a day after the shares touched a new 52-week high of $83.04 following the fourth-quarter results, which was also the first earnings report after the company's merger with IMS Health. Analyst Eric Coldwell said Quintiles has...

Citing CVS Health Corp (NYSE: CVS)'s exposure to drug pricing and the ongoing PBM debate, Baird downgraded shares of the company to Neutral. The firm doesn't think fundamentals are good either. Healthcare Supply Chain Concerns A Top Issue In 2017 Analyst Eric Coldwell noted that his healthcare...